Indications for: VAXCHORA
Immunization against disease caused by Vibrio cholerae serogroup 01 in individuals 2–64 years of age traveling to cholera-affected areas.
Limitations of Use:
Efficacy not established in persons living in cholera-affected areas or persons with pre-existing immunity due to previous exposure to V. cholerae or receipt of a cholera vaccine. Not shown to protect against disease caused by V. cholerae serogroup 0139 or other non-01 serogroups.
Adults and Children:
<2yrs: not established. For oral administration only. Avoid food or drink for 60mins before and after administration. Give single oral dose of 100mL (for individuals 6–64yrs) or 50mL (for children 2–<6yrs) a minimum of 10 days before potential cholera exposure. Safety and efficacy of revaccination with Vaxchora: not established.
Severe allergic reaction to any previous cholera vaccine.
Immunocompromised, elderly (≥65yrs). Considering whether to administer to individuals with immunocompromised close contacts. Pregnancy.
Avoid use within 14 days of systemic antibiotics. Give vaccine ≥10 days prior to antimalarial prophylaxis with chloroquine. Concomitant immunosuppressive therapy (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, high-dose corticosteroids): may get suboptimal response.
Tiredness, headache, abdominal pain, nausea/vomiting, lack of appetite, diarrhea.
To enroll patients in the pregnancy exposure registry call (800) 533-5899.
Generic Drug Availability:
Single-dose carton—2 packets (buffer component + active component)